About Us About Us

Management Team

The drug development process is complex. Our management team offers deep expertise in all aspects of the process to drive products toward commercialization.


m_baker

Mark R. Baker

Chief Executive Officer

Mr. Baker is Chief Executive Officer and a director of the Company. In 2005 Mr. Baker joined the Company as Senior Vice President & General Counsel and Secretary, in 2008 he became Executive Vice President, Corporate, in 2009 he became President of the Company and in March 2011 he was appointed Chief Executive of the Company. He became director of the Company in 2009. Prior to joining the Company Mr. Baker was Chief Business Officer and a director of New York Water Taxi, a privately-held ferry operation in New York City (2003-2005), Executive Vice President and Chief Legal Officer of Continental Grain Company, a privately-held international agri-business and financial concern (1997-2001) and a partner and Co-Chairman of the Capital Markets Group of Dewey Ballantine, a New York law firm (1979-1997). Mr. Baker serves as Chairman of the Board of Directors of the Brooklyn Bridge Park Conservancy. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.


v_wong

Pat Fabbio

Senior Vice President and Chief Financial Officer

Mr. Fabbio joined the Company in November 2015 as Senior Vice President and Chief Financial Officer. Prior to Progenics, he was Chief Financial Officer of electroCore, a privately-held bioelectric medicine healthcare company, and Vice President, Finance for NPS Pharmaceuticals, Inc., a publicly traded, global rare disease company that was acquired by Shire. Mr. Fabbio has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies including: Vice President, Finance, Catalent Pharma Solutions; Chief Financial Officer of Ikano Therapeutics; senior corporate finance, commercial, and transactional roles at Sanofi; and Corporate Controller for Biomatrix Inc., a publicly traded biotechnology company that was acquired by Genzyme. He graduated from Pace University with a B.B.A. in Accounting and from the Stern School of Business at New York University, with a Master’s Degree in Finance. He received his certified public accountant license in New Jersey.


v_wong

Vivien Wong Ph.D.

Executive Vice President, Development

Dr. Wong joined the Company in September 2007 and currently serves as Executive Vice President, Development. For three years prior to joining Progenics, Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004, she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.


Jessica Jensen

Jessica Jensen, MPH

Vice President, Clinical Development

Ms. Jensen joined the Company in 2014 and is currently Vice President of Clinical Development. From 2014 to 2016, she held positions of increasing responsibility in Progenics across clinical operations, program management, and clinical development. She is a multi-disciplined and dynamic leader, with over 10 years of oncology experience across all phases of clinical research. Prior to joining Progenics, Jessica advanced immunotherapy programs at the Ludwig Institute for Cancer Research where she led global clinical trials of combination therapies with immune checkpoint inhibitors and cancer vaccines. Prior thereto, Jessica led clinical operations activities for an orphan drug program at Gentium SpA, a biopharmaceutical company since acquired by Jazz Pharmaceuticals, and she supported client programs as well as the development of a contract research organization business unit at US Oncology. Jessica began her career in Statistical Programming and Biostatistics after receiving a Master of Public Health degree in Epidemiology & Biostatistics from the George Washington University.


Thomas Strack

Thomas Strack

Vice President, Clinical Affairs

Dr. Strack joined the Company as VP Clinical Affairs in September 2015. He has more than 20 years of experience in developing novel pharmaceutical products in various therapeutic areas including metabolic/endocrine, oncology and CNS, and held various leadership positions at Eli Lilly & Company (regulatory oncology lead), Pfizer Inc. (Group lead endocrine/metabolic/ophthalmology), Takeda Global Research and Development (Head metabolic clinical development), and Asubio Pharmaceuticals (Head R/D). Dr. Strack received his MD and doctorate degrees from Johannes Gutenberg University, Germany, and is board-certified in internal medicine and endocrinology.


Bryce Tenbarge

Bryce Tenbarge

Vice President, Commercial

Mr. Tenbarge joined the Company in August 2016 as Vice President, Commercial. Prior to joining Progenics, he was Vice President of Marketing and Commercialization at Celldex Therapeutics, a publicly traded biotechnology company. Mr. Tenbarge has more than 15 years of commercial leadership experience with highly specialized products including: Senior Director of Global Oncology Marketing at Teva Pharmaceuticals and a variety of roles of increasing responsibility at Bristol-Myers Squibb in professional and payer marketing, market research and business intelligence. Mr. Tenbarge started his career as a commodity trader at Archer Daniels Midland in Chicago prior to receiving his MBA from The Ross School of Business at the University of Michigan.